Last 12 months
Inside the activity.
0 purchase rows · 145 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 9 |
| Dec 2025 | 0 | 8 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 41 |
| Apr 2026 | 0 | 26 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 11 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 18 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2021 Filed Jun 12, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,895 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-040100 · doc4.xml · derivative · entry 11 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,850 Underlying: Common Stock · 3,895 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 11, 2021 Filed Jun 12, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,895 | $38.41 | $149,606.95 |
DisclosureSEC source: 0001209191-21-040100 · doc4.xml · nonDerivative · entry 8 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.79 to 38.76, inclusive. Read SEC document |
| June 11, 2021 Filed Jun 12, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,895 | $6.32 | $24,616.40 |
DisclosureSEC source: 0001209191-21-040100 · doc4.xml · nonDerivative · entry 7 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| June 10, 2021 Filed Jun 12, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,895 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-040100 · doc4.xml · derivative · entry 10 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,745 Underlying: Common Stock · 3,895 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 10, 2021 Filed Jun 12, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 2,795 | $37.87 | $105,846.65 |
DisclosureSEC source: 0001209191-21-040100 · doc4.xml · nonDerivative · entry 6 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.33 to 38.25, inclusive. Read SEC document |
| June 10, 2021 Filed Jun 12, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 1,100 | $36.77 | $40,447.00 |
DisclosureSEC source: 0001209191-21-040100 · doc4.xml · nonDerivative · entry 5 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,155 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $36.26 to 37.12, inclusive. Read SEC document |
| June 10, 2021 Filed Jun 12, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,895 | $6.32 | $24,616.40 |
DisclosureSEC source: 0001209191-21-040100 · doc4.xml · nonDerivative · entry 4 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-039637 · doc4.xml · derivative · entry 7 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 10,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 10,000 | $35.60 | $356,000.00 |
DisclosureSEC source: 0001209191-21-039637 · doc4.xml · nonDerivative · entry 5 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.26 to 35.825, inclusive. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 10,000 | $6.55 | $65,500.00 |
DisclosureSEC source: 0001209191-21-039637 · doc4.xml · nonDerivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,895 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-040100 · doc4.xml · derivative · entry 9 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,640 Underlying: Common Stock · 3,895 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 500 | $36.50 | $18,250.00 |
DisclosureSEC source: 0001209191-21-040100 · doc4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $36.41 to 36.59, inclusive. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,395 | $35.91 | $121,914.45 |
DisclosureSEC source: 0001209191-21-040100 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,860 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.40 to 36.37, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,895 | $6.32 | $24,616.40 |
DisclosureSEC source: 0001209191-21-040100 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-039637 · doc4.xml · derivative · entry 6 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 10,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 1,599 | $37.85 | $60,522.15 |
DisclosureSEC source: 0001209191-21-039637 · doc4.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.64 to 38.03, inclusive. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 8,401 | $36.90 | $309,996.90 |
DisclosureSEC source: 0001209191-21-039637 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,203 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $36.58 to 37.18, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 10,000 | $6.55 | $65,500.00 |
DisclosureSEC source: 0001209191-21-039637 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| May 18, 2021 Filed May 19, 2021 20:00 UTC |
Palaniappan JyotiSVP, Diagnostics, T-Detect
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 651 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001209191-21-034234 · doc4.xml · derivative · entry 3 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,996 Underlying: Common Stock · 651 shares Expires 2030-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| May 18, 2021 Filed May 19, 2021 20:00 UTC |
Palaniappan JyotiSVP, Diagnostics, T-Detect
|
SaleCommon Stock | 651 | $35.00 | $22,785.00 |
DisclosureSEC source: 0001209191-21-034234 · doc4.xml · nonDerivative · entry 2 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,158 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. Read SEC document |
| May 18, 2021 Filed May 19, 2021 20:00 UTC |
Palaniappan JyotiSVP, Diagnostics, T-Detect
|
Exercise / conversionCommon Stock | 651 | $22.55 | $14,680.05 |
DisclosureSEC source: 0001209191-21-034234 · doc4.xml · nonDerivative · entry 1 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. Read SEC document |
| May 18, 2021 Filed May 20, 2021 00:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-034235 · doc4.xml · derivative · entry 3 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,000 Underlying: Common Stock · 2,500 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| May 18, 2021 Filed May 20, 2021 00:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
SaleCommon Stock | 2,500 | $35.00 | $87,500.00 |
DisclosureSEC source: 0001209191-21-034235 · doc4.xml · nonDerivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| May 18, 2021 Filed May 20, 2021 00:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
Exercise / conversionCommon Stock | 2,500 | $7.80 | $19,500.00 |
DisclosureSEC source: 0001209191-21-034235 · doc4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:00 UTC |
THORSEN HENNINGSVP, Commercial Operations
|
GrantStock Option (Right to Buy) · Derivative | 72,653 | $0.00 Strike: $34.41 | $0.00 |
DisclosureSEC source: 0001209191-21-034233 · doc4.xml · derivative · entry 2 THORSEN HENNING · CIK 0001854505 · SVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,653 Underlying: Common Stock · 72,653 shares Expires 2031-05-17 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on May 15, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:00 UTC |
THORSEN HENNINGSVP, Commercial Operations
|
GrantCommon Stock | 29,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034233 · doc4.xml · nonDerivative · entry 1 THORSEN HENNING · CIK 0001854505 · SVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,061 Read SEC document |
| May 14, 2021 Filed May 18, 2021 00:00 UTC |
LO FRANCISChief People Officer
|
Exercise / conversionStock Option (Right To Buy) · Derivative | 2,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-033313 · doc4.xml · derivative · entry 4 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,000 Underlying: Common Stock · 2,000 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on May 6, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| May 14, 2021 Filed May 18, 2021 00:00 UTC |
LO FRANCISChief People Officer
|
SaleCommon Stock | 2,000 | $33.80 | $67,600.00 |
DisclosureSEC source: 0001209191-21-033313 · doc4.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. Read SEC document |
| May 14, 2021 Filed May 18, 2021 00:00 UTC |
LO FRANCISChief People Officer
|
Exercise / conversionCommon Stock | 2,000 | $7.80 | $15,600.00 |
DisclosureSEC source: 0001209191-21-033313 · doc4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. Read SEC document |
| May 12, 2021 Filed May 13, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-032438 · doc4.xml · derivative · entry 7 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 10,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 12, 2021 Filed May 13, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 10,000 | $32.63 | $326,300.00 |
DisclosureSEC source: 0001209191-21-032438 · doc4.xml · nonDerivative · entry 5 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $32.21 to 32.82, inclusive. Read SEC document |
| May 12, 2021 Filed May 13, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 10,000 | $6.55 | $65,500.00 |
DisclosureSEC source: 0001209191-21-032438 · doc4.xml · nonDerivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| May 11, 2021 Filed May 13, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-032438 · doc4.xml · derivative · entry 6 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 10,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| May 11, 2021 Filed May 13, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 7,031 | $31.84 | $223,867.04 |
DisclosureSEC source: 0001209191-21-032438 · doc4.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $31.52 to 32.12, inclusive. Read SEC document |
| May 11, 2021 Filed May 13, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 2,969 | $30.81 | $91,474.89 |
DisclosureSEC source: 0001209191-21-032438 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,635 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $30.488 to 31.48, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| May 11, 2021 Filed May 13, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 10,000 | $6.55 | $65,500.00 |
DisclosureSEC source: 0001209191-21-032438 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| May 06, 2021 Filed May 8, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,895 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-031082 · doc4.xml · derivative · entry 7 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,535 Underlying: Common Stock · 3,895 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 06, 2021 Filed May 8, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 847 | $36.38 | $30,813.86 |
DisclosureSEC source: 0001209191-21-031082 · doc4.xml · nonDerivative · entry 5 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.99 to 36.70, inclusive. Read SEC document |
| May 06, 2021 Filed May 8, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,048 | $35.51 | $108,234.48 |
DisclosureSEC source: 0001209191-21-031082 · doc4.xml · nonDerivative · entry 4 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,207 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $34.97 to 35.95, inclusive. Read SEC document |
| May 06, 2021 Filed May 8, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,895 | $6.32 | $24,616.40 |
DisclosureSEC source: 0001209191-21-031082 · doc4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| May 06, 2021 Filed Jun 12, 2021 01:00 UTC Amendment |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,895 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-040099 · doc4a.xml · derivative · entry 7 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,535 Underlying: Common Stock · 3,895 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 06, 2021 Filed Jun 12, 2021 01:00 UTC Amendment |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 847 | $36.38 | $30,813.86 |
DisclosureSEC source: 0001209191-21-040099 · doc4a.xml · nonDerivative · entry 5 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.99 to 36.70, inclusive. Read SEC document |
| May 06, 2021 Filed Jun 12, 2021 01:00 UTC Amendment |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,048 | $35.51 | $108,234.48 |
DisclosureSEC source: 0001209191-21-040099 · doc4a.xml · nonDerivative · entry 4 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,207 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $34.97 to 35.95, inclusive. Read SEC document |
| May 06, 2021 Filed Jun 12, 2021 01:00 UTC Amendment |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,895 | $6.32 | $24,616.40 |
DisclosureSEC source: 0001209191-21-040099 · doc4a.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| May 05, 2021 Filed May 8, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,895 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-031082 · doc4.xml · derivative · entry 6 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,430 Underlying: Common Stock · 3,895 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 05, 2021 Filed May 8, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,195 | $35.43 | $113,198.85 |
DisclosureSEC source: 0001209191-21-031082 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.18 to 35.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| May 05, 2021 Filed May 8, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,895 | $6.32 | $24,616.40 |
DisclosureSEC source: 0001209191-21-031082 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| May 05, 2021 Filed Jun 12, 2021 01:00 UTC Amendment |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,895 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-040099 · doc4a.xml · derivative · entry 6 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,430 Underlying: Common Stock · 3,895 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 05, 2021 Filed Jun 12, 2021 01:00 UTC Amendment |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,895 | $35.43 | $137,999.85 |
DisclosureSEC source: 0001209191-21-040099 · doc4a.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.18 to 35.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| May 05, 2021 Filed Jun 12, 2021 01:00 UTC Amendment |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,895 | $6.32 | $24,616.40 |
DisclosureSEC source: 0001209191-21-040099 · doc4a.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.